P. Kellie Turner

1.1k total citations · 1 hit paper
44 papers, 833 citations indexed

About

P. Kellie Turner is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, P. Kellie Turner has authored 44 papers receiving a total of 833 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 7 papers in Genetics. Recurrent topics in P. Kellie Turner's work include Advanced Breast Cancer Therapies (16 papers), HER2/EGFR in Cancer Research (9 papers) and Chronic Lymphocytic Leukemia Research (7 papers). P. Kellie Turner is often cited by papers focused on Advanced Breast Cancer Therapies (16 papers), HER2/EGFR in Cancer Research (9 papers) and Chronic Lymphocytic Leukemia Research (7 papers). P. Kellie Turner collaborates with scholars based in United States, United Kingdom and Japan. P. Kellie Turner's co-authors include Palaniappan Kulanthaivel, Stephen D. Hall, Edward M. Chan, Jane Royalty, Jeffrey G. Suico, Steven E. Nissen, Cynthia Griggs Fleming, Giacomo Ruotolo, Laura F. Michael and Paul H. Berg and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Oncology.

In The Last Decade

P. Kellie Turner

43 papers receiving 808 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation

2023 112 citations Stephen J. Nicholls, Steven E. Nissen et al. JAMA profile →

Peers

Countries citing papers authored by P. Kellie Turner

Since Specialization

Citations

This map shows the geographic impact of P. Kellie Turner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Kellie Turner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Kellie Turner more than expected).

Fields of papers citing papers by P. Kellie Turner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Kellie Turner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Kellie Turner. The network helps show where P. Kellie Turner may publish in the future.

Co-authorship network of co-authors of P. Kellie Turner

This figure shows the co-authorship network connecting the top 25 collaborators of P. Kellie Turner. A scholar is included among the top collaborators of P. Kellie Turner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Kellie Turner. P. Kellie Turner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preclinical and clinical evaluation of a novel TRPA1 antagonist LY3526318 2025 ·Pain ·Lisa M. Broad, Jeffrey G. Suico, P. Kellie Turner, Si Nie, Kirk W. Johnson, Helen Sanger, Lindsay A. Wegiel, David C. Sperry, Daniel G. Remick, Magdalene M. Moran, (unknown), Donato del Camino, Xinyuan Wu, Jayhong A. Chong, Nathaniel T. Blair, A Wilke	3
2	Abemaciclib does not increase the corrected QT interval in healthy participants 2023 ·Clinical and Translational Science ·(unknown), Alan Y. Chiang, Jane Royalty, (unknown), Palaniappan Kulanthaivel, P. Kellie Turner	5
3	Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation breakdown → 2023 ·JAMA ·Stephen J. Nicholls, Steven E. Nissen, Cynthia Griggs Fleming, Shweta Urva, Jeffrey G. Suico, Paul H. Berg, Helle Linnebjerg, Giacomo Ruotolo, P. Kellie Turner, Laura F. Michael	112
4	Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials 2021 ·Cancer Science ·Masakazu Toi, Kenichi Inoue, Norikazu Masuda, Hiroji Iwata, Joohyuk Sohn, In Hae Park, Seock‐Ah Im, Shin‐Cheh Chen, Sotaro Enatsu, P. Kellie Turner, Valérie André, Molly Catherine Hardebeck, Sachi Sakaguchi, Matthew P. Goetz, George W. Sledge	16
5	Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer 2020 ·Drug Metabolism and Disposition ·P. Kellie Turner, Stephen D. Hall, Sonya C. Chapman, Jessica Rehmel, Jane Royalty, Yingying Guo, Palaniappan Kulanthaivel	17
6	Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling 2020 ·The Journal of Clinical Pharmacology ·Maria M. Posada, Bridget L. Morse, P. Kellie Turner, Palaniappan Kulanthaivel, Stephen D. Hall, Gemma L. Dickinson	39
7	Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study 2018 ·Clinical Cancer Research ·Edward S. Kim, Karen Kelly, Luis Paz‐Ares, Pilar Garrido, Shadia I. Jalal, Daruka Mahadevan, Martin Gutierrez, Mariano Provencio, Eric Schaefer, (unknown), (unknown), P. Kellie Turner, (unknown), Richard P. Beckmann, Anwar Hossain, William J. John, Jonathan W. Goldman	17
8	Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer. 2017 ·Journal of Clinical Oncology ·Sara M. Tolaney, Nancy U. Lin, Donald Thornton, Suzanne Klise, Timothy M. Costigan, P. Kellie Turner, Carey K. Anders	41
9	A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients 2017 ·Clinical Pharmacokinetics ·Sonya C. Tate, (unknown), Palaniappan Kulanthaivel, Edward M. Chan, P. Kellie Turner, Damien M. Cronier	55
10	Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam 2017 ·European Journal of Drug Metabolism and Pharmacokinetics ·E.J. Perkins, Maria M. Posada, P. Kellie Turner, Jill Chappell, (unknown), Chris Twelves	5
11	A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer 2016 ·Clinical Cancer Research ·Lee S. Rosen, Jonathan W. Goldman, Alain P. Algazi, P. Kellie Turner, Brian A. Moser, Tianle Hu, Xuejing Aimee Wang, Jay Tuttle, Volker Wacheck, James E. Wooldridge, Michaela S. Banck	57
12	Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer 2016 ·Cancer Chemotherapy and Pharmacology ·Yutaka Fujiwara, Kenji Tamura, Shunsuke Kondo, Yuko Tanabe, Satoru Iwasa, Akihiko Shimomura, Shigehisa Kitano, K. OGASAWARA, P. Kellie Turner, (unknown), Hiroya Asou, Edward M. Chan, Noboru Yamamoto	50
13	Understanding Disease–Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window 2015 ·Clinical Pharmacology & Therapeutics ·(unknown), P Kulanthaivel, P. Kellie Turner, (unknown), John R. Baldwin, (unknown), Celine Pitou, S D Hall	46
14	An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors 2014 ·Investigational New Drugs ·Robert M. Jotte, Daniel D. Von Hoff, Fadi Braiteh, Carlos Becerra, Donald Richards, David A. Smith, Lawrence Garbo, Joe Stephenson, Paul Conkling, (unknown), Jian Chen, P. Kellie Turner, Kay Hoong Chow, (unknown), Robert Ilaria	10
15	A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors 2013 ·Cancer Chemotherapy and Pharmacology ·Yutaka Fujiwara, Yukio Ando, Toru Mukohara, Naomi Kiyota, Naoko Chayahara, Ayako Mitsuma, (unknown), Masataka Sawaki, Robert Ilaria, P. Kellie Turner, Jumpei Funai, (unknown), Hironobu Minami	5
16	Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children 2005 ·Cancer Chemotherapy and Pharmacology ·P. Kellie Turner, Lisa Iacono, John C. Panetta, Victor M. Santana, Najat C. Daw, Amar Gajjar, Clinton F. Stewart	7
17	Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer 2004 ·Cancer Chemotherapy and Pharmacology ·Janet A. Houghton, István Peták, David M. Tillman, Leslie Douglas, Lee S. Schwartzberg, (unknown), John C. Panetta, (unknown), P. Kellie Turner	20
18	Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin. 2002 ·PubMed ·Lee S. Schwartzberg, István Peták, Clinton F. Stewart, P. Kellie Turner, (unknown), David M. Tillman, Leslie Douglas, Ming Tan, (unknown), Rudolf Mihalik, Alva B. Weir, Kurt W. Tauer, (unknown), Janet A. Houghton	27
19	Serum concentrations and bioavailability of rifampicin and isoniazid in combination. 1976 ·British Journal of Clinical Pharmacology ·(unknown), T. Taylor, P. Kellie Turner, (unknown)	23
20	SIDE-EFFECTS OF DRUGS. 1965 ·PubMed ·(unknown), Malcolm Rowland, P. Kellie Turner	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact